Deep Bio’s AI Algorithm Helps Risk Stratification for Prostate Cancer
Summary
Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that Dr. Lotan from Johns Hopkins Medicine presented their collaborative research which utilized the deep learning-based algorithm for prostate cancer diagnosis support at a podium session in the American Urological Association (AUA) annual meeting 2023. This joint research compared human pathologists and an AI algorithm in grading prostate biopsy specimens to predict biochemical recurrence after radical prostatectomy. The company also continues to build its presence in the global market through collaboration with overseas digital pathology solution providers in the US, Europe, and India. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.